Search

everythinglearnresearchcommunity

for

Search:↓

KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The user must stop minoxidil due to a heart murmur and is considering alternatives like nanoxidil or stemoxydine while continuing dutasteride. Suggestions include adding pyrilutamide and alfatradiol or switching to topical minoxidil at a lower concentration.

A user shared how they bought an 18-month supply of finasteride for $23.50 in Turkey by purchasing 5mg pills and splitting them. They also mentioned buying other medications like painkillers and antibiotics from local pharmacies.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

A 23-year-old started using 1mg Finasteride and Minoxidil twice daily on September 14 and saw positive results without side effects, boosting confidence and gym performance. They asked if switching from generic Finasteride to Propecia-brand would cause any changes.

A 23-year-old has been using finasteride 5mg daily since age 19 and added dutasteride 0.5mg twice a week to prevent hairline recession. They report no side effects and credit early treatment for maintaining their hair.

A 24-year-old male is increasing his dutasteride dosage from 0.5mg to 1mg daily due to continued hair thinning despite using finasteride, dutasteride, and topical minoxidil. Another user suggests trying oral minoxidil for potentially better results.

Creatine may cause hair shedding and texture changes, with mixed user experiences. Combining creatine with finasteride doesn't always prevent these effects, possibly due to individual DHT sensitivity.

A 32-year-old male used 1.25mg oral finasteride daily and 1ml topical minoxidil twice daily for 24 weeks, experiencing improved skin and hair growth with initial side effects that resolved after three weeks. He plans to try dermastamping to address a stubborn cowlick area.

The user is seeking advice on sourcing finasteride, dutasteride, and minoxidil, as their doctors are unwilling to prescribe both finasteride/dutasteride and minoxidil simultaneously. They are also looking for sources of GHK-Cu and RU58841 in the USA, with suggestions including using services like Hims, ro.co, and Musely.

Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).

A 28-year-old man regrew hair using 1mg finasteride, 2.5mg oral minoxidil, a multivitamin, and a derma roller over 1 year and 9 months. Initial side effects resolved, and he maintains his hair with continued treatment.

The person is using 1mg of finasteride daily, 2mg of minoxidil, and weekly dermarolling with a 1mm needle. They sometimes use topical minoxidil as well.

A 19-year-old experiencing mild hair loss plans to start finasteride and use Nizoral, avoiding minoxidil for now. Others share their experiences with finasteride, noting minimal side effects and advising against worrying about potential negative effects.

A 23-year-old male shares his 136-day progress using a hair loss treatment regimen of daily Dutasteride 0.5mg, topical Minoxidil 5% with Tretinoin, and Nizoral every other day, reporting no side effects and significant hair regrowth. He notes high energy and libido, with no shedding, and attributes most progress to Dutasteride.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

A 20-year-old male experienced early hair thinning due to male pattern baldness and successfully thickened his hair using oral finasteride and topical minoxidil. The conversation highlights the importance of early action and overcoming fear of medication side effects.

OP wants to buy fluridil from China and needs advice on mixing it in a topical solution due to budget constraints. They cannot afford Eucapil.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The user is using RU58841, Revivogen, Regenepure ketoconazole shampoo, and plans to use a stimufield cap to address hair loss. They aim to avoid finasteride and minoxidil while hoping to stop hair loss and regrow hair.

Dutasteride at 0.5mg has not cleared acne and has caused arm hair thickening. The user plans to increase the dose to 1mg.

Seeking adenosine shampoo or conditioner in the UK without minoxidil. Topical adenosine solution also considered.

The user reports progress in hair regrowth using a daily routine of 0.5mg Dutasteride, 5% Minoxidil foam, and Olly hair gummies, while discontinuing rosemary water. They are hopeful for continued improvement and have received positive feedback on their progress.

Best 2% Minox brand for mixing with pyrilutamide powder and retinoic acid sought. Advice on specific treatments discussed.

Pyrilutamide, a drug in phase 3 trials in China, potentially becoming available in late 2023 or early 2024; Finasteride being used as a current treatment for hair loss; and the possibility of joining a group buy for black market versions of Pyrilutamide.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.

The conversation discusses hair loss treatments, specifically using dutasteride (0.5mg daily) with no side effects reported after two months. It also mentions the health benefits of one meal per day and the low incidence of side effects.